Denosumab Wins for Bone Mets in Breast Cancer | Dental Implant and Bone Regeneration | Scoop.it
Women with metastatic breast cancer had significantly fewer bone-related complications when treated with denosumab (Xgeva) instead of zoledronic acid (Zometa), according to randomized trial results.

 

 

More: http://www.medpagetoday.com/HematologyOncology/BreastCancer/34204